267 related articles for article (PubMed ID: 32156806)
1. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection.
Andersson JA; Peniche AG; Galindo CL; Boonma P; Sha J; Luna RA; Savidge TC; Chopra AK; Dann SM
mBio; 2020 Mar; 11(2):. PubMed ID: 32156806
[TBL] [Abstract][Full Text] [Related]
2. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.
Andersson JA; Sha J; Kirtley ML; Reyes E; Fitts EC; Dann SM; Chopra AK
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109161
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Inflammation Reversibly Alters the Microbiota to Drive Susceptibility to Clostridioides difficile Colonization in a Mouse Model of Colitis.
Barron MR; Sovacool KL; Abernathy-Close L; Vendrov KC; Standke AK; Bergin IL; Schloss PD; Young VB
mBio; 2022 Aug; 13(4):e0190422. PubMed ID: 35900107
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.
Winston JA; Rivera AJ; Cai J; Thanissery R; Montgomery SA; Patterson AD; Theriot CM
Infect Immun; 2020 May; 88(6):. PubMed ID: 32205405
[No Abstract] [Full Text] [Related]
5. Investigating the impact of antibiotic-induced dysbiosis on protection from
Uddin MJ; Thompson B; Leslie JL; Fishman C; Sol-Church K; Kumar P; Petri WA
mBio; 2024 Mar; 15(3):e0333823. PubMed ID: 38376154
[TBL] [Abstract][Full Text] [Related]
6. The microbial metabolite urolithin A reduces
Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
[No Abstract] [Full Text] [Related]
7. Aging impairs protective host defenses against Clostridioides (Clostridium) difficile infection in mice by suppressing neutrophil and IL-22 mediated immunity.
Peniche AG; Spinler JK; Boonma P; Savidge TC; Dann SM
Anaerobe; 2018 Dec; 54():83-91. PubMed ID: 30099125
[TBL] [Abstract][Full Text] [Related]
8. Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection.
Cribas ES; Denny JE; Maslanka JR; Abt MC
Infect Immun; 2021 Apr; 89(5):. PubMed ID: 33649048
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Activity of Tannic Acid
Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
[TBL] [Abstract][Full Text] [Related]
10. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
Andersson JA; Fitts EC; Kirtley ML; Ponnusamy D; Peniche AG; Dann SM; Motin VL; Chauhan S; Rosenzweig JA; Sha J; Chopra AK
Antimicrob Agents Chemother; 2016 Jun; 60(6):3717-29. PubMed ID: 27067323
[TBL] [Abstract][Full Text] [Related]
11. ZupT Facilitates Clostridioides difficile Resistance to Host-Mediated Nutritional Immunity.
Zackular JP; Knippel RJ; Lopez CA; Beavers WN; Maxwell CN; Chazin WJ; Skaar EP
mSphere; 2020 Mar; 5(2):. PubMed ID: 32161145
[No Abstract] [Full Text] [Related]
12. Repurposing auranofin as a Clostridioides difficile therapeutic.
Hutton ML; Pehlivanoglu H; Vidor CJ; James ML; Thomson MJ; Lyras D
J Antimicrob Chemother; 2020 Feb; 75(2):409-417. PubMed ID: 31642901
[TBL] [Abstract][Full Text] [Related]
13. Dietary Xanthan Gum Alters Antibiotic Efficacy against the Murine Gut Microbiota and Attenuates
Schnizlein MK; Vendrov KC; Edwards SJ; Martens EC; Young VB
mSphere; 2020 Jan; 5(1):. PubMed ID: 31915217
[TBL] [Abstract][Full Text] [Related]
14. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
Bassis CM; Theriot CM; Young VB
Antimicrob Agents Chemother; 2014 May; 58(5):2767-74. PubMed ID: 24590475
[TBL] [Abstract][Full Text] [Related]
15. Frontiers in antibiotic alternatives for
Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
17. Protection from Lethal Clostridioides difficile Infection via Intraspecies Competition for Cogerminant.
Leslie JL; Jenior ML; Vendrov KC; Standke AK; Barron MR; O'Brien TJ; Unverdorben L; Thaprawat P; Bergin IL; Schloss PD; Young VB
mBio; 2021 Mar; 12(2):. PubMed ID: 33785619
[No Abstract] [Full Text] [Related]
18. Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.
Tubau-Juni N; Bassaganya-Riera J; Leber AJ; Alva SS; Hontecillas R
Inflamm Bowel Dis; 2024 Jan; 30(1):103-113. PubMed ID: 37436905
[TBL] [Abstract][Full Text] [Related]
19. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
